TEVA-PANTOPRAZOLE 20 MG
PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) : 20 MG · DIN 02285479 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-PANTOPRAZOLE?
TEVA-PANTOPRAZOLE 20 MG contains PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02285479, held by TEVA CANADA LIMITED, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Mar-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-PANTOPRAZOLE used for?
Treatment of duodenal ulcer, gastric ulcer, reflux esophagitis, symptomatic GERD, and prevention of NSAID-induced gastrointestinal lesions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02285479 |
|---|---|
| Brand name | TEVA-PANTOPRAZOLE |
| Generic / active ingredient | PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) : 20 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 20 MG |
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BC02 PANTOPRAZOLE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Mar-2023 |
| Original market date | 2006-09-19 00:00:00 |
How is it administered?
40 mg once daily for ulcers, GERD, and reflux esophagitis. 20 mg once daily for prevention of NSAID-induced lesions. Swallow whole with fluid in the morning.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: Standard Teva storage for these tablets, though specific text was cut off in provided snippet, section 11 is listed in TOC).
How is it supplied?
20 mg: Bottles of 100 tablets. 40 mg: Bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity to pantoprazole, substituted benzimidazoles, or any ingredient in the formulation. Co-administration with rilpivirine.
Warnings and precautions
May mask gastric malignancy. Increased risk of Clostridium difficile-associated diarrhea, bone fractures (long-term/high-dose), hypomagnesemia, and Vitamin B12 deficiency. SCARs reported.
Is PANTOPRAZOLE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SIVEM PHARMACEUTICALS ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A02BC02 PANTOPRAZOLE. 39 of 98 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-PANTOPRAZOLE SODIUM | 40 MG | TABLET (DELAYED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02481588 |
| APO-PANTOPRAZOLE | 20 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02292912 |
| APO-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02292920 |
| AURO-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | AURO PHARMA INC | MARKETED | DIN 02415208 |
| BIO-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | BIOMED PHARMA | MARKETED | DIN 02445867 |
| JAMP PANTOPRAZOLE SODIUM | 20 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02392615 |
| JAMP PANTOPRAZOLE SODIUM | 40 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02392623 |
| JAMP-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02357054 |
| M-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | MANTRA PHARMA INC | MARKETED | DIN 02467372 |
| MAR-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02416565 |
Who else supplies PANTOPRAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PANTOPRAZOLE appears in 1645 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.